Compare BridgeBio Pharma Inc (BBIO) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Roundhill Magnificent Seven ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Roundhill Magnificent Seven ETF trades at $68.42. Which is the better fit depends on your goals.
| BBIO | MAGS | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | Sector/Thematic |
52-Week High | $90.17 | $70.94 |
52-Week Low | $47.29 | $55.39 |
Enterprise Value | $18.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
MAGS trades at $69.07, up 0.71% today, with a bullish technical signal from moving averages but neutral oscillators. Recent news highlights underperformance versus the S&P 500 and concerns over AI spending pressure on big tech balance sheets. The ETF has gained 181% since launch but faces challenges from equal-weighted concentration in the Magnificent Seven stocks.
The outlook is mixed: technical strength supports near-term upside, but fundamental risks from high AI capital expenditure and shifting investor sentiment toward broader market exposure pose headwinds. Investment opportunity hinges on AI revenue growth outpacing costs, while key risks include sector rotation and valuation compression.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
